Ovarian Cancer Clinical Roundup
(MedPage Today) Sept 23, 2020 - An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.
(ICR [UK]) Sept 18, 2020 - Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated advanced ovarian cancer remain disease free after five years, a new study shows.
(Reuters) Sept 18, 2020 - Europe’s health regulator has recommended the approval of GSK’s cancer treatment Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemotherapy, the British drugmaker said on Friday.
(AstraZeneca) Sept 18, 2020 - Five-year data from the SOLO-1 Phase III trial is the longest follow-up analysis for any PARP inhibitor in the 1st-line maintenance setting.
AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in...
(JAMA Oncol) - 2020-09-24
(JAMA Netw Open) - 2020-09-01
(Clin Cancer Res) - 2020-09-28